Hemostemix Inc. (TSXV:HEM)
Canada
· Delayed Price · Currency is CAD Hemostemix Statistics
Total Valuation
Hemostemix has a market cap or net worth of CAD 18.89 million. The enterprise value is 22.62 million.
| Market Cap | 18.89M |
| Enterprise Value | 22.62M |
Important Dates
The last earnings date was Wednesday, June 4, 2025.
| Earnings Date | Jun 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Hemostemix has 145.31 million shares outstanding. The number of shares has increased by 13.73% in one year.
| Current Share Class | 145.31M |
| Shares Outstanding | 145.31M |
| Shares Change (YoY) | +13.73% |
| Shares Change (QoQ) | -20.03% |
| Owned by Insiders (%) | 8.50% |
| Owned by Institutions (%) | n/a |
| Float | 127.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | -2.53 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.60 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.31
| Current Ratio | 0.31 |
| Quick Ratio | 0.29 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.05 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -247.10% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 114.44% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 9 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +188.89% in the last 52 weeks. The beta is -0.43, so Hemostemix's price volatility has been lower than the market average.
| Beta (5Y) | -0.43 |
| 52-Week Price Change | +188.89% |
| 50-Day Moving Average | 0.11 |
| 200-Day Moving Average | 0.13 |
| Relative Strength Index (RSI) | 54.34 |
| Average Volume (20 Days) | 121,780 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -2.61M |
| Pretax Income | -3.43M |
| Net Income | -3.43M |
| EBITDA | -2.61M |
| EBIT | -2.61M |
| Earnings Per Share (EPS) | -0.04 |
Balance Sheet
The company has 965,164 in cash and 4.69 million in debt, giving a net cash position of -3.73 million or -0.03 per share.
| Cash & Cash Equivalents | 965,164 |
| Total Debt | 4.69M |
| Net Cash | -3.73M |
| Net Cash Per Share | -0.03 |
| Equity (Book Value) | -7.47M |
| Book Value Per Share | -0.05 |
| Working Capital | -2.43M |
Cash Flow
| Operating Cash Flow | -1.44M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Hemostemix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.73% |
| Shareholder Yield | n/a |
| Earnings Yield | -18.13% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 30, 2020. It was a reverse split with a ratio of 0.05.
| Last Split Date | Dec 30, 2020 |
| Split Type | Reverse |
| Split Ratio | 0.05 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |